Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 2389038, 4 pages
http://dx.doi.org/10.1155/2016/2389038
Case Report

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

1Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, CO, USA
2Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
3University of Birmingham Medical School, Edgbaston, Birmingham, UK
4Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
5Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

Received 8 August 2016; Revised 3 October 2016; Accepted 4 October 2016

Academic Editor: Eduardo Arellano-Rodrigo

Copyright © 2016 Maheen Z. Abidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of reactivation pulmonary tuberculosis in a retired physician while on treatment with ruxolitinib. We also review the literature on opportunistic infections following use of ruxolitinib. Our case highlights the importance of screening for latent tuberculosis in patients from highly endemic areas prior to start of therapy with ruxolitinib.